Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PANCREAS: PurIST Classification-Guided Adaptive Neoadjuvant Chemotherapy in Pancreatic Cancer
NCT04683315Phase 2Recruiting
- Sponsor
- Medical College of Wisconsin
- Start
- Apr 2021
- Primary completion
- Dec 2027
- Modality
- DNA Intercalators/Alkylators, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of fluorouracil, folinic acid, irinotecan, oxaliplatin, gemcitabine in pancreatic cancer (PC), sponsored by Medical College of Wisconsin. Started Apr 2021; status: recruiting.
02
Drugs
fluorouracilfolinic acidirinotecanoxaliplatingemcitabine
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on NCT04683315.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04683315.